Skip to content
AgingNexus
☰ Menu
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effect of Rapamycin in Ovarian Aging

Authors not listed

Columbia University · 2023

Deregulated nutrient-sensing Rapamycin / mTOR inhibition Human Randomized controlled trial
＋ Sign in to save

Abstract

The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-05-29 MST

Cite this

APA
Anonymous. (2023). Effect of Rapamycin in Ovarian Aging. <em>Columbia University</em>. https://clinicaltrials.gov/study/NCT05836025
Vancouver
Anonymous. Effect of Rapamycin in Ovarian Aging. Columbia University. 2023.
BibTeX
@misc{anon2023Effect, title = {Effect of Rapamycin in Ovarian Aging}, author = {Anonymous}, journal = {Columbia University}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings